Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3581 | Serologic SARS-CoV-2 screening Wiki | 0.58 |
| drug311 | Anti-SARS-CoV2 serological controls and serum neutralization Wiki | 0.58 |
| drug694 | CERC-002 Wiki | 0.58 |
Navigate: Correlations HPO
There are 3 clinical trials
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.
Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 60. Time: From Day 0 to Day 60Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 30. Time: From Day 0 to Day 30Description: Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 30 and Day 60. Time: From Day 30 to Day 60Description: Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.
Measure: Anti-SARS-Cov2 seroprevalence at Day 0. Time: Day 0Description: Correlation between seroconversion (measured in blood sample) at Day 60 and sex
Measure: Correlation between seroconversion and socio-demographic factors - sex Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and age
Measure: Correlation between seroconversion and socio-demographic factors - age Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)
Measure: Correlation between seroconversion and professional factors - job type Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type
Measure: Correlation between seroconversion and professional factors - personal protective equipment type Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals
Measure: Correlation between seroconversion and non-professional factors - contact with infected individuals Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment
Measure: Correlation between seroconversion and non-professional factors - wearing of professional equipment Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures
Measure: Correlation between seroconversion and non-professional factors - respect of barrier gestures Time: Day 60In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible. The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.
Description: The percentage of the study population with positive serological status will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0
Measure: Proportion anti-SARS-CoV2 seropositive Time: Day 0Description: Among anti-SARS-CoV2 seropositive participants, the percentage of asymptomatic participants will be determined. COVID-19 symptoms will be measured using a questionnaire.
Measure: Proportion of asymptomatic anti-SARS-CoV2 seropositive participants Time: Day 0Description: The serological results obtained using the reference ELISA test results (detecting the presence of IgG and IgM antobodies) and using a second ELISA test detecting the presence of antibodies specifically directed against the Receptor Binding Domain and the Spike protein trimer of SARS-CoV2 virus will be compared.
Measure: Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies) Time: Day 0Description: Among anti-SARS-CoV2 seropositive participants, the percentage of participants with a positive response to serum neutralization will be determined.
Measure: Proportion of serum neutralization positive Time: Day 0Description: The evolution of the antibody level over time will be determined using repeated serodiagnoses at 3 and 9 months.
Measure: Change of antibody level over time Time: 3 months and 9 months after Day 0Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission is by droplet route, with an R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. During the period of containment, the majority of students from the Lyon-Bron Military Medical Schools were sent as reinforcement in Army Training Hospitals and in the Military Reanimation Unit (Mulhouse). Some students developed symptomatic forms of SARS-Cov-2 infection, documented by positive PCR, during Operation Resilience or on their return from the mission. The Lyon-Bron Military Medical Schools staff, exposed both to the initial phase of the epidemic and to national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus.
Description: The proportion of anti-SARS-CoV2 seropositive participants will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0.
Measure: Proportion of anti-SARS-CoV2 seropositive participants Time: Day 0Description: The proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants) will be determined. COVID-19 symptoms will be measured using a questionnaire.
Measure: Proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants) Time: Day 0Description: Correlation coefficient between medical risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Measure: Correlation coefficient between medical risk factors and a positive serology Time: Day 0Description: Correlation coefficient between epidemiological risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Measure: Correlation coefficient between epidemiological risk factors and a positive serology Time: Day 0Description: Correlation coefficient between social risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Measure: Correlation coefficient between social risk factors and a positive serology Time: Day 0Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports